Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives

Low-density lipoprotein lowering with statins has convincingly and consistently proven to reduce cardiovascular events in both primary and secondary prevention. However, despite high-dose statin therapy, residual cardiovascular risk remains and many patients also do not tolerate statins. Ezetimibe w...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradhan, Akshyaya, Bhandari, Monika, Sethi, Rishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338976/
https://www.ncbi.nlm.nih.gov/pubmed/32670636
http://dx.doi.org/10.1155/2020/9815016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338976/
https://www.ncbi.nlm.nih.gov/pubmed/32670636
http://dx.doi.org/10.1155/2020/9815016

Ejemplares similares